Enrique Grande, One Oncology Madrid Program Director of Quirónsalud, Adjunct Professor at The University of Texas MD Anderson Cancer Center, shared on X:
“Histological subtypes of urothelial carcinoma — micropapillary, plasmacytoid, sarcomatoid, squamous — represent biologically distinct phenotypes that do not conform to a one-size-fits-all approach.
Frequently understaged on TURBT, with variable response to standard systemic therapy.”
Title: Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications
Authors: Can Aydogdu, Laura Bukavina, Liang Cheng, Hikmat A. Al-Ahmadie, Omar Alhalabi, Jason R. Brown, Antonio Lopez-Beltran, Petros Grivas, Clara Hwang, G. Daniel Grass, Ashish M. Kamat, Jonathan Chatzkel, Omar Mian, Andrea Necchi, Jeff Ross, Andrea B. Apolo, Philippe E. Spiess, Roger Li
Read also “Sequencing After Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Carcinoma” on OncoDaily.
